Financial Ratios Lineage Cell Therapeutics, Inc.
Stocks
LCTX
US53566P1093
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.230 USD | -3.15% |
|
+1.65% | -26.35% |
| 05-13 | Lineage Cell Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026 | |
| 05-12 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -21.78 | -9.44 | -11.8 | -12.53 | -12.06 | |||||
Return on Total Capital | -31.93 | -16.6 | -18.82 | -18.58 | -21.73 | |||||
Return On Equity % | -46.52 | -32.37 | -32.07 | -26.73 | -105.3 | |||||
Return on Common Equity | -45.66 | -31.74 | -31.42 | -26.25 | -103.36 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 67.15 | 95.05 | 92.5 | -34.81 | -22.8 | |||||
SG&A Margin | 419.53 | 153.08 | 153.96 | 191.29 | 126.82 | |||||
EBITDA Margin % | -1.11K | -148.22 | -229.3 | -219.7 | -144.82 | |||||
EBITA Margin % | -1.13K | -152.18 | -235.58 | -225.88 | -149.62 | |||||
EBIT Margin % | -1.13K | -153.17 | -237.04 | -226.11 | -149.62 | |||||
Income From Continuing Operations Margin % | -996.77 | -179.24 | -240.12 | -195.62 | -435.33 | |||||
Net Income Margin % | -990.99 | -178.69 | -240.2 | -195.9 | -436.47 | |||||
Net Avail. For Common Margin % | -990.99 | -178.69 | -240.2 | -195.9 | -436.47 | |||||
Normalized Net Income Margin | -678.36 | -99.85 | -140.35 | -122.49 | -232.14 | |||||
Levered Free Cash Flow Margin | -862.84 | 90.7 | -115.92 | -134.74 | -76.79 | |||||
Unlevered Free Cash Flow Margin | -862.84 | 90.7 | -115.92 | -134.74 | -76.79 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.03 | 0.1 | 0.08 | 0.09 | 0.13 | |||||
Fixed Assets Turnover | 0.83 | 2.79 | 1.71 | 2.07 | 3.2 | |||||
Receivables Turnover (Average Receivables) | 0.17 | 0.58 | 17.17 | 13.74 | 13.23 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.37 | 3.16 | 2.14 | 3.65 | 5.2 | |||||
Quick Ratio | 2.32 | 3.06 | 2.02 | 3.47 | 5.04 | |||||
Operating Cash Flow to Current Liabilities | -0.5 | 0.06 | -1.59 | -1.65 | -1.66 | |||||
Days Sales Outstanding (Average Receivables) | 2.14K | 634.73 | 21.26 | 26.64 | 27.58 | |||||
Average Days Payable Outstanding | 787.59 | 1.49K | 1.21K | 46.07 | 35.89 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 3.08 | 5.42 | 4.76 | 3.26 | 5.58 | |||||
Total Debt / Total Capital | 2.99 | 5.14 | 4.54 | 3.16 | 5.29 | |||||
LT Debt/Equity | 2.17 | 4.09 | 3.34 | 1.77 | 3.61 | |||||
Long-Term Debt / Total Capital | 2.1 | 3.88 | 3.19 | 1.71 | 3.42 | |||||
Total Liabilities / Total Assets | 47.92 | 41.83 | 38.6 | 31.98 | 61.5 | |||||
EBIT / Interest Expense | - | - | - | - | - | |||||
EBITDA / Interest Expense | - | - | - | - | - | |||||
(EBITDA - Capex) / Interest Expense | - | - | - | - | - | |||||
Total Debt / EBITDA | -0.06 | -0.18 | -0.14 | -0.13 | -0.12 | |||||
Net Debt / EBITDA | 1.15 | 2.48 | 1.59 | 2.3 | 2.68 | |||||
Total Debt / (EBITDA - Capex) | -0.06 | -0.18 | -0.14 | -0.12 | -0.12 | |||||
Net Debt / (EBITDA - Capex) | 1.14 | 2.43 | 1.54 | 2.24 | 2.62 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 137.73 | 238.7 | -39.16 | 6.19 | 53.24 | |||||
Gross Profit, 1 Yr. Growth % | 102.29 | 379.42 | -40.79 | -55.5 | 0.36 | |||||
EBITDA, 1 Yr. Growth % | 98.04 | -54.92 | -5.88 | 1.75 | 1.01 | |||||
EBITA, 1 Yr. Growth % | 94.21 | -54.34 | -5.82 | 1.82 | 1.51 | |||||
EBIT, 1 Yr. Growth % | 86.07 | -54.24 | -5.85 | 1.3 | 1.4 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 109.19 | -39.1 | -18.5 | -13.49 | 241.01 | |||||
Net Income, 1 Yr. Growth % | 108.33 | -38.93 | -18.22 | -13.39 | 241.41 | |||||
Normalized Net Income, 1 Yr. Growth % | 108.07 | -50.14 | -14.49 | -7.32 | 190.4 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 90.02 | -40.83 | -19.58 | -25.3 | 197.02 | |||||
Accounts Receivable, 1 Yr. Growth % | 1.27M | -99.42 | 150.84 | -14.36 | 144.83 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -13.46 | 16.44 | -15.97 | -7.8 | 6.87 | |||||
Total Assets, 1 Yr. Growth % | 61.69 | -29.15 | -18.31 | 12.08 | -0.56 | |||||
Tangible Book Value, 1 Yr. Growth % | -9.79 | -54 | -61.28 | 242.26 | -89.72 | |||||
Common Equity, 1 Yr. Growth % | -4.14 | -20.47 | -13.53 | 23.59 | -43.16 | |||||
Cash From Operations, 1 Yr. Growth % | 19.28 | -104.49 | -2.8K | -19.16 | -18.07 | |||||
Capital Expenditures, 1 Yr. Growth % | 453.12 | 21.47 | 63.2 | -16.17 | -7.61 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -378.64 | -135.6 | -177.75 | 23.43 | -12.66 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -378.64 | -135.6 | -177.75 | 23.43 | -12.66 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 11.13 | 183.76 | 43.55 | -19.62 | 27.56 | |||||
Gross Profit, 2 Yr. CAGR % | -3.08 | 211.42 | 68.48 | -51.35 | -33.17 | |||||
EBITDA, 2 Yr. CAGR % | 25.33 | -5.51 | -34.86 | -2.14 | 1.38 | |||||
EBITA, 2 Yr. CAGR % | 24.18 | -5.83 | -34.42 | -2.08 | 1.66 | |||||
EBIT, 2 Yr. CAGR % | 20.71 | -7.72 | -34.36 | -2.34 | 1.35 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 91.27 | 12.87 | -29.54 | -16.03 | 71.76 | |||||
Net Income, 2 Yr. CAGR % | 91.68 | 12.8 | -29.33 | -15.84 | 71.96 | |||||
Normalized Net Income, 2 Yr. CAGR % | 28 | 1.85 | -34.71 | -10.97 | 64.06 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 80.29 | 6.04 | -31.02 | -22.49 | 48.95 | |||||
Accounts Receivable, 2 Yr. CAGR % | 1.15K | 761.68 | -87.9 | 46.57 | 44.8 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -22.8 | 0.38 | -1.08 | -11.98 | -0.74 | |||||
Total Assets, 2 Yr. CAGR % | 17.94 | 7.03 | -23.92 | -4.32 | 5.57 | |||||
Tangible Book Value, 2 Yr. CAGR % | -19.84 | -35.58 | -57.8 | 15.11 | -40.67 | |||||
Common Equity, 2 Yr. CAGR % | -9.64 | -12.69 | -17.07 | 3.38 | -16.19 | |||||
Cash From Operations, 2 Yr. CAGR % | -14.12 | -76.85 | 10.11 | 366.96 | -18.62 | |||||
Capital Expenditures, 2 Yr. CAGR % | -10.3 | 154.03 | 40.8 | 16.96 | -12 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 0.26 | -0.4 | -47.39 | -2.04 | 3.83 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 0.26 | -0.4 | -47.39 | -2.04 | 3.83 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -4.53 | 61.12 | 69.83 | 29.83 | -0.33 | |||||
Gross Profit, 3 Yr. CAGR % | -14.64 | 65.14 | 79.07 | 4.3 | -38.07 | |||||
EBITDA, 3 Yr. CAGR % | 8.62 | -10.87 | -5.63 | -24.42 | -1.1 | |||||
EBITA, 3 Yr. CAGR % | 8.09 | -11.04 | -5.83 | -24.06 | -0.9 | |||||
EBIT, 3 Yr. CAGR % | 6.28 | -12.64 | -7.1 | -24.15 | -1.11 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -2.57 | 30.61 | 1.26 | -24.55 | 33.97 | |||||
Net Income, 3 Yr. CAGR % | -2.2 | 30.92 | 1.33 | -24.37 | 34.22 | |||||
Normalized Net Income, 3 Yr. CAGR % | 5.32 | -6.52 | -3.92 | -26.62 | 32.03 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -10.31 | 24.36 | -3.3 | -29.16 | 21.29 | |||||
Accounts Receivable, 3 Yr. CAGR % | 160.41 | -2.86 | 471.08 | -76.76 | 73.9 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -5.84 | -11.47 | -5.4 | -3.38 | -6.1 | |||||
Total Assets, 3 Yr. CAGR % | 19.74 | -0.48 | -2.19 | -13.44 | -3.08 | |||||
Tangible Book Value, 3 Yr. CAGR % | -27.39 | -33.38 | -45.64 | -15.21 | -48.54 | |||||
Common Equity, 3 Yr. CAGR % | -0.58 | -13.41 | -12.97 | -5.28 | -15.31 | |||||
Cash From Operations, 3 Yr. CAGR % | -8.62 | -67.88 | 13.09 | -0.67 | 161.42 | |||||
Capital Expenditures, 3 Yr. CAGR % | -36.99 | -2.09 | 119.19 | 18.45 | 8.12 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 20.27 | -29 | -8.29 | -30.09 | -5.71 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 20.49 | -29 | -8.29 | -30.09 | -5.71 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -6.03 | 33.57 | 12.39 | 22 | 51.46 | |||||
Gross Profit, 5 Yr. CAGR % | -12.13 | 33.55 | 12.04 | 1.28 | 18.16 | |||||
EBITDA, 5 Yr. CAGR % | -2.27 | -10.22 | -11.47 | -7.48 | -2.89 | |||||
EBITA, 5 Yr. CAGR % | -2.42 | -10.2 | -11.49 | -7.55 | -2.9 | |||||
EBIT, 5 Yr. CAGR % | -3.55 | -11.14 | -12.35 | -8.66 | -3.81 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 18.37 | 2.5 | -14.42 | 9.46 | 25.1 | |||||
Net Income, 5 Yr. CAGR % | 5.08 | 5.63 | -14.12 | 9.71 | 25.2 | |||||
Normalized Net Income, 5 Yr. CAGR % | 2.89 | -7.45 | -13.01 | -8.33 | 19.01 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -5.11 | -2.38 | -19.25 | 2.93 | 14.94 | |||||
Accounts Receivable, 5 Yr. CAGR % | 121.34 | -37.22 | -23.69 | 14.51 | 229.86 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -2.5 | 0.5 | -3.96 | -11.67 | -3.56 | |||||
Total Assets, 5 Yr. CAGR % | 4.13 | -6.52 | -0.13 | -2.04 | 0.84 | |||||
Tangible Book Value, 5 Yr. CAGR % | -20.26 | -36.58 | -41.56 | -17.09 | -43.7 | |||||
Common Equity, 5 Yr. CAGR % | -4.8 | -14.73 | -7.54 | -7.05 | -14.27 | |||||
Cash From Operations, 5 Yr. CAGR % | -11.06 | -48.94 | -1.55 | -6.29 | -0.86 | |||||
Capital Expenditures, 5 Yr. CAGR % | -32.5 | -20.81 | -13.79 | 5.13 | 52.16 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 4.42 | -9.59 | -13.6 | -19.24 | -3.62 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 4.56 | -9.71 | -13.5 | -19.24 | -3.62 |
- Stock Market
- Stocks
- LCTX Stock
- Financials Lineage Cell Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















